Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Update

Intensity Therapeutics Inc. (NASDAQ:INTS) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totaling 68,355 shares, a decrease of 58.0% from the July 15th total of 162,597 shares. Based on an average trading volume of 23,378 shares, the days-to-cover ratio is currently 2.9 days. Approximately 2.7% of the shares of the stock are short sold.

Intensity Therapeutics Price Performance

NASDAQ:INTS traded down $0.04 during trading hours on Friday, reaching $3.96. 38,949 shares of the company were exchanged, compared to its average volume of 26,156. The company has a current ratio of 5.00, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. The firm has a market cap of $12.91 million, a PE ratio of -0.69 and a beta of 2.76. Intensity Therapeutics has a twelve month low of $3.51 and a twelve month high of $43.50. The stock’s 50-day moving average is $4.25 and its 200-day moving average is $5.55.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24). On average, sell-side analysts anticipate that Intensity Therapeutics will post -2.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Benchmark restated a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Citigroup reiterated a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Intensity Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

Institutional Investors Weigh In On Intensity Therapeutics

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in shares of Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after acquiring an additional 201,357 shares during the last quarter. Legacy Advisors LLC purchased a new position in shares of Intensity Therapeutics in the fourth quarter valued at approximately $63,000. State Street Corp boosted its stake in shares of Intensity Therapeutics by 839.3% in the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares during the last quarter. Corient Private Wealth LLC acquired a new stake in shares of Intensity Therapeutics in the fourth quarter worth approximately $41,000. Finally, Jane Street Group LLC acquired a new stake in shares of Intensity Therapeutics in the fourth quarter worth approximately $26,000. 3.74% of the stock is currently owned by institutional investors and hedge funds.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.